J&J to Acquire Halda Therapeutics in $3.05B Cancer Therapy Deal

Johnson & Johnson has announced a definitive agreement to acquire Halda Therapeutics OpCo, Inc., a clinical-stage biotechnology company developing next-generation targeted cancer medicines. The all-cash deal, valued at $3.05 billion, represents a major strategic addition to J&J’s expanding oncology portfolio and is expected to close within the next few months, pending antitrust clearance and standard regulatory approvals.

The acquisition centers on Halda’s proprietary RIPTAC™ (Regulated Induced Proximity Targeting Chimera) platform, a technology designed to develop oral therapies that selectively kill cancer cells by exploiting induced proximity mechanisms. RIPTAC™ medicines aim to overcome a persistent challenge in cancer treatment: resistance to standard therapies. By leveraging this novel approach, Halda’s platform is being applied across multiple solid tumors, with potential applications beyond oncology as well.

Halda’s lead candidate, HLD-0915, is a clinical-stage therapy targeting prostate cancer, a disease projected to reach 1.7 million new global diagnoses by 2030. Rising incidence, treatment resistance, and limited long-term therapeutic options have created a significant unmet need in advanced prostate cancer. HLD-0915 is designed as a once-daily oral therapy that uses precision targeting to eliminate cancer cells even after resistance develops, offering a promising new pathway for patients with aggressive or treatment-refractory disease.

In addition to HLD-0915, the acquisition includes several earlier-stage candidates addressing breast, lung, and other solid tumors. Halda’s broad pipeline may also enable the development of targeted therapies outside of oncology, reflecting the versatility of the RIPTAC™ platform.

Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine at Johnson & Johnson, emphasized the strategic importance of the acquisition. She noted that integrating Halda’s technology, pipeline, and team with J&J’s global research, commercial, and manufacturing capabilities will accelerate the development of transformative therapies and reinforce J&J’s leadership in cancer innovation.

John C. Reed, M.D., Ph.D., Executive Vice President of Innovative Medicine R&D at J&J, highlighted the strength of early data for HLD-0915, citing “impressive preliminary efficacy and a strong early safety profile” in prostate cancer studies. He added that J&J is eager to advance the ongoing Phase 1/2 trial and to accelerate additional RIPTAC™-based candidates through development.

The acquisition underscores J&J’s long-term commitment to strengthening its oncology portfolio with therapies that feature differentiated, complementary mechanisms of action. If successful, Halda’s assets could significantly expand treatment options for patients facing cancers with limited or diminishing responses to current therapies.

With this investment, Johnson & Johnson is positioning itself at the forefront of innovative targeted cancer therapy development, betting on a platform that could shape future standards of care across multiple tumor types.